Dive into the archives.
- Biogen Reports 2 More Cases of PML with Tysabri
By THOMAS GRYTA
Two more cases of a rare brain infection have emerged in users of the multiple-sclerosis drug Tysabri, sold by Biogen Idec Inc. and Elan PLC, the first such incidences since Biogen stopped updating investors of the situation in July.
At that time, Biogen had confirmed 11 cases of progressive multifocal leukoencephalopathy, or PML, since [...]
- Elan and Biogen are in a Fight
Elan starts legal action in drug row with Biogen
By Andrew Jack
Published: August 6 2009 22:34 | Last updated: August 6 2009 22:34
Elan has launched legal action to prevent the “irreparable injury” that would be caused by the collapse of its partnership with Biogen Idec over its pivotal multiple sclerosis drug.
The Ireland-based pharmaceuticals company is challenging [...]
- 11th Case of PML Reported With Tysabri
The 11the patient on Tysabri has developed a potentially deadly brain infection.
This is what happened when three people who were on Tysabri and other medications for Multiple Sclerosis had previously contracted the brain infection and two died, according to InjuryBoard.com which tracks such drug reactions. Then, the drug was taken off the market briefly.
Biogen Idec, [...]
- Hot off the AAN Press: Tysabri Promotes Remyelination
July 4, 2009
Biogen Idec (NASDAQ: BIIB) and Elan Corporation (NYSE: ELN) announced results of a study demonstrating that Tysabri® (natalizumab) promoted regeneration and stabilization of damage done to the myelin sheath, as measured by advanced MRI technology. Damage to the myelin sheath causes the symptoms of multiple sclerosis (MS). Additional posters were presented during the [...]
- Biogen Reports 13th Case of PML
By KEITH J. WINSTEIN
Biogen Idec Inc.’s disclosure of a debilitating brain infection in a patient taking its Tysabri multiple-sclerosis medicine sparked a selloff in shares of the biotechnology company Monday.
The disclosure, made Friday evening, marks the 13th case of the infection, called progressive multifocal leukoencephalopathy or PML, in a Tysabri patient. Three of the patients [...]
- 10th PML Case Confirmed by Biogen
Biogen Idec Inc. has reported a new case of a potentially lethal brain inflammation in a patient using its drug Tysabri, the tenth such case since the drug was reintroduced three years ago.
The company said late Friday it confirmed the presence of progressive multifocal leukoencephalopathy, or PML, on Tuesday. Biogen said the patient, who lives [...]
- Tysabri Side Effects Linked to 9th PML Infection Case
A new case of a rare, often lethal, brain infection has been linked to the multiple sclerosis drug Tysabri, making it the ninth case of progressive multifocal leukoencephalopathy (PML) infection potentially caused by side effects of Tysabri since the drug was put back on the market in July 2006.
Biogen Idec Inc., the maker of Tysabri, [...]
- Biogen Says Eighth Patient Has Infection From Tysabri
By Tom Randall
June 12 (Bloomberg) — Biogen Idec said a patient taking its multiple sclerosis drug Tysabri was diagnosed with a life-threatening brain illness, the eighth case reported in the last year.
The patient was confirmed to have progressive multifocal leukoencephalopathy, or PML, on June 10, according to a report on Cambridge, Massachusetts-based Biogen’s Web site. [...]
- Hot off the AAN Press: Fingolimod effective but safety an issue
UPDATE 3-Novartis MS drug effective but safety an issue
ZURICH, April 29 (Reuters) – Novartis AG said 80-83 percent of those taking its multiple sclerosis drug FTY720 are relapse-free compared with 69 percent on the leading current treatment, but it reported a new patient death.
Novartis said the patient died from aspiration pneumonia related to a [...]
- Hot off the AAN Press: Tysabri May Reverse MS Damage
UPDATE 1-Elan’s Tysabri may reverse MS damage, shares up
April 29 (Reuters) – Elan’s Tysabri drug may be able to reverse damage caused by multiple sclerosis, the Irish drugmaker and its U.S. partner Biogen Idec said on Wednesday, boosting Elan’s shares 10 percent.
Data released by the companies at the American Academy of Neurology showed Tysabri promoted [...]
